1.	Record Nr.	UNINA9910506387603321
	Titolo	New Rapid-acting Antidepressants / / edited by Kenji Hashimoto, Mario Manto
	Pubbl/distr/stampa	Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021
	ISBN	3-030-79790-2
	Edizione	[1st ed. 2021.]
	Descrizione fisica	1 online resource (152 pages)
	Collana	Contemporary Clinical Neuroscience, , 2627-5341
	Disciplina	616.8527061
	Soggetti	Neurosciences Neuroscience
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
	Note generali	Includes index.
	Nota di contenuto	(R)-ketamine: A new rapid-acting antidepressant -- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms -- Predictable biomarkers for rapid-acting antidepressant response to ketamine -- Nitrous Oxide: an old compound with emerging psychotropic properties -- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants -- AMPA receptor potentiators as potential rapid-acting antidepressants -- mGlu2/3 receptor antagonists as rapid-acting antidepressants -- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.
	Sommario/riassunto	This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists,

psychiatrists, and those who want to learnabout CNS drugs at the graduate level.